Health · 1 views
Twice-daily radiation linked to better quality of life in lung cancer trial
Those results showed that adding atezolizumab did not improve overall survival (OS) for this patient population.
AI Summary
A trial evaluating twice‑daily radiation combined with the immunotherapy drug atezolizumab for patients with limited‑stage small‑cell lung cancer reported that the regimen was linked to improved quality‑of‑life outcomes. The study, identified as NRG‑LU005 (NCT03811002), added atezolizumab to standard concurrent chemoradiation and presented its primary endpoint results at the 2024 American Society for Radiation Oncology annual meeting.
Read full article on Medical XpressAI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Next generation theranostic pair offers new strategy to detect and treat metastatic kidney cancerContinue reading
- Physical exams alone may not reliably diagnose pneumonia in children, national study findsContinue reading
- New philosophical framework reframes moral distress in health careContinue reading
- Monoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six monthsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow